A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma

Trial Profile

A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Dinutuximab (Primary) ; Irinotecan (Primary) ; Temsirolimus (Primary) ; Sargramostim; Sargramostim; Temozolomide
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2017 Status changed from suspended to active, no longer recruiting.
    • 19 May 2017 Status changed from recruiting to suspended due to completion of accrual goal
    • 02 Aug 2016 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top